Armata says AP-SA02 genetic diversity may boost killing of some Staph aureus isolates in clinical testing
ARMP•AP-SA02 data to be presented at ISSSI 2026
Armata Pharmaceuticals will present new AP-SA02 data at ISSSI 2026 on Sept. 21, 2026.
Results suggest controlled genetic diversity in the phage cocktail can improve killing of some Staphylococcus aureus clinical isolates.
Manufacturing is designed to keep this diversity consistent across clinical lots, positioning it as a deliberate product attribute.
The update supports plans to move AP-SA02 toward a Phase 3 superiority study in complicated S. aureus bacteremia.
